Modality
Radioligand
MOA
ALKi
Target
TIM-3
Pathway
PI3K/AKT
RettMGSLE
Development Pipeline
Preclinical
~Sep 2018
→ ~Dec 2019
Phase 1
Mar 2020
→ Oct 2030
Phase 1Current
NCT04760179
787 pts·MG
2021-02→2030-10·Recruiting
NCT04920206
1,423 pts·SLE
2020-03→TBD·Completed
2,210 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-10-044.5y awayPh2 Data· MG
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Complet…
P1/2
Recruit…
Catalysts
Ph2 Data
2030-10-04 · 4.5y away
MG
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04760179 | Phase 1/2 | MG | Recruiting | 787 | SRI-4 |
| NCT04920206 | Phase 1/2 | SLE | Completed | 1423 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| ALN-3284 | Alnylam | Phase 2/3 | CDK2 | |
| Doxasotorasib | Samsung Biologics | Phase 2/3 | CFTR |